Literature DB >> 4026489

Time course of serum cardiac enzymes after intracoronary thrombolytic therapy. Creatine kinase, creatine kinase MB isozyme, lactate dehydrogenase, and serum glutamic-oxaloacetic transaminase.

J Y Wei, J E Markis, M Malagold, W Grossman.   

Abstract

We analyzed the time course of serum creatine kinase (CK), the CK MB isozyme, lactate dehydrogenase (LDH), and serum glutamic-oxaloacetic transaminase (SGOT) activity and calculated rates of increase and decline for CK in 24 consecutive patients with acute myocardial infarction (AMI) who received intracoronary thrombolytic therapy. In 19 patients with successfully reperfused infarcts, peak CK activity occurred at 14.1 +/- 1.1 hours after onset of symptoms, the maximal rate of CK rise was 595 +/- 102 IU/L/hr, and the fractional disappearance rate (Kd) was (86 +/- 6) X 10(-5)/min. The peak CK MB activity occurred at 12.9 +/- 0.8 hours and the MB Kd was (223 +/- 39) X 10(-5)/min. In five patients in the nonreperfused group the peak CK (24.9 +/- 4.5 hours) and CK MB (22.7 +/- 3.3 hours) activity occurred later, the maximal rate of CK rise (281 +/- 37 IU/L/hr) was less, and the CK Kd [(68 +/- 5) X 10(-5)/min] and MB Kd [(116 +/- 28) X 10(-5)/min] were lower. The peak CK, CK MB, cumulative CK release, and area under the curve were not different. Except for a shortened time to peak SGOT in the reperfused (17.1 +/- 1.3 hours) compared with the nonreperfused (29.1 +/- 5.6 hours) groups, the time course of LDH and SGOT were not different. Thus, the initial serum CK kinetics and time to peak SGOT may be useful in assessing the reperfusion status in patients with AMI receiving thrombolytic therapy without coronary angiography or in those who may have spontaneous recanalization.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4026489

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  6 in total

1.  The diagnosis of myocardial infarction in the first 16 hours after the onset of chest pain by measurement of log CK slope.

Authors:  P J Mullen
Journal:  Postgrad Med J       Date:  1991-03       Impact factor: 2.401

Review 2.  Intravenous streptokinase. A reappraisal of its therapeutic use in acute myocardial infarction.

Authors:  K L Goa; J M Henwood; J F Stolz; M S Langley; S P Clissold
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  Achievement of coronary artery patency by use of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.

Authors:  W S Hillis; R S Hornung; K J Hogg; N Hockings; J M Burns; F G Dunn
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  Possible role of thromboxane A2 in remote hind limb preconditioning-induced cardioprotection.

Authors:  Roohani Sharma; Puneet Kaur Randhawa; Nirmal Singh; Amteshwar Singh Jaggi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-11-03       Impact factor: 3.000

Review 5.  Streptokinase. A review of its pharmacology and therapeutic efficacy in acute myocardial infarction in older patients.

Authors:  P E Battershill; P Benfield; K L Goa
Journal:  Drugs Aging       Date:  1994-01       Impact factor: 3.923

6.  Serum interferon-gamma-inducible protein 10 level was increased in myocardial infarction patients, and negatively correlated with infarct size.

Authors:  Kazuya Koten; Satoshi Hirohata; Toru Miyoshi; Hiroko Ogawa; Shinichi Usui; Ryoko Shinohata; Mutsumi Iwamoto; Tomoki Kitawaki; Shozo Kusachi; Kosaku Sakaguchi; Tohru Ohe
Journal:  Clin Biochem       Date:  2007-10-11       Impact factor: 3.281

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.